The overall incidence of EGFR-TKIs-related lethal toxic reactions is 1.33%,[15] from the current post-marketing safety report of EGFR-TKI, afatinib has a higher proportion of adverse reactions in causing skin and gastrointestinal reactions, gefitinib seems to be prone to ILD and liver damage, and QT interval prolongation seems to be more frequent in patients treated with osimertinib. The gene discussed is EGFR; the disease is interstitial lung disease.